XML 40 R27.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

REVENUE (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2024
Revenue from Contract with Customer [Abstract] |
Schedule of Revenue | Total revenues during the three and six months ended June 30, 2024 and 2023 were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Product sales, net: |  |  |  |  |  |  |
IBSRELA | $ | 35,445 |  |  | $ | 18,309 |  |  | $ | 63,806 |  |  | $ | 29,664 |
XPHOZAH | 37,146 |  |  | — |  |  | 52,297 |  |  | — |
Total product sales, net | 72,591 |  |  | 18,309 |  |  | 116,103 |  |  | 29,664 |
Product supply revenue | 13 |  |  | 3,260 |  |  | 2,139 |  |  | 3,262 |
Licensing revenue | 19 |  |  | 764 |  |  | 36 |  |  | 776 |
Non-cash royalty revenue related to the sale of future royalties | 599 |  |  | — |  |  | 967 |  |  | — |
Total revenues | $ | 73,222 |  |  | $ | 22,333 |  |  | $ | 119,245 |  |  | $ | 33,702 |
Schedule of Revenue from Customers as a Percentage of Total Product Revenue, Net | Revenue from Customers who contributed greater than 10% of our total gross product revenue during the three and six months ended June 30, 2024 and 2023 was as follows (as a percentage of total gross product revenue):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
BioRidge Pharma, LLC | 50.8 | % |  | 20.0 | % |  | 46.3 | % |  | 19.0 | %
AmerisourceBergen Drug Corporation | 14.2 | % |  | 21.1 | % |  | 15.8 | % |  | 21.3 | %
Cardinal Health | 13.5 | % |  | 22.4 | % |  | 14.6 | % |  | 22.3 | %
McKesson Corporation | 13.0 | % |  | 18.4 | % |  | 13.2 | % |  | 19.4 | %
Schedule of Chargebacks, Discounts and Reserve Balances | The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
| Discounts and Chargebacks |  | Rebates, Wholesaler and GPO Fees |  | Copay and Returns |  | Total
Balance as of December 31, 2023 | $ | 478 |  |  | $ | 4,234 |  |  | $ | 3,916 |  |  | $ | 8,628 |
Provisions | 5,928 |  |  | 24,938 |  |  | 13,258 |  |  | 44,124 |
Credits/payments | (5,473) |  |  | (19,334) |  |  | (10,265) |  |  | (35,072) |
Balance as of June 30, 2024 | $ | 933 |  |  | $ | 9,838 |  |  | $ | 6,909 |  |  | $ | 17,680 |

X
- Definition Schedule Of Gross To Net Sales Accruals + References No definition available. + Details
Name: | ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock
Namespace Prefix: | ardx_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration